Similar Papers

Paper Title
Journal
Date
Author
Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified?
Robert J Fontana
Gastroenterology | VOL. 130
Robert J FontanaRobert J Fontana
01 Apr 2006
Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients
Gloria Taliani ...
Gastroenterology | VOL. 130
Gloria Taliani, et. al.Gloria Taliani ...
01 Apr 2006
Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
Michael Von Wagner ... Stefan Zeuzem
Gastroenterology | VOL. 129
Michael Von Wagner, et. al.Michael Von Wagner ... Stefan Zeuzem
01 Aug 2005
Virological Response in Patients with??Hepatitis C Virus Genotype 1b and??a??High Viral Load
Gotaro Yamada ... Shiro Iino
Clinical Drug Investigation | VOL. 28
Gotaro Yamada, et. al.Gotaro Yamada ... Shiro Iino
01 Jan 2008
View more papers

More From: Clinical and Molecular Hepatology

Paper Title
Journal
Date
Author
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study.
Shou-Wu Lee ...
Clinical and molecular hepatology | VOL. -
Shou-Wu Lee, et. al.Shou-Wu Lee ...
05 Feb 2025
Deciphering adenosine signaling in hepatocellular carcinoma: pathways, prognostic models, and therapeutic implications.
Huihai Yang ... Terence Kin Wah Lee
Clinical and molecular hepatology | VOL. -
Huihai Yang, et. al.Huihai Yang ... Terence Kin Wah Lee
05 Feb 2025
Baveno VI-SSM was able to stratify the risk of portal hypertension-related events in patients with HBV-related cirrhosis.
Haiyu Wang ... Jinjun Chen
Clinical and molecular hepatology | VOL. -
Haiyu Wang, et. al.Haiyu Wang ... Jinjun Chen
05 Feb 2025
FIB-4plus Score: A novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): An international multicenter study.
Bingtian Dong ... Xiaolong Qi
Clinical and molecular hepatology | VOL. -
Bingtian Dong, et. al.Bingtian Dong ... Xiaolong Qi
05 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.